Editorial disclosure: This article is original educational commentary based on the cited literature. It summarizes and interprets published evidence rather than reproducing source text. Clinical decisions should be based on the full original publications, current guidelines, regulatory status, and individual patient factors.
Clinical context
The treatment of chronic kidney disease is moving toward layered kidney protection. ACE inhibitors or ARBs, SGLT2 inhibitors and, in selected patients, mineralocorticoid receptor antagonists have each contributed to a broader strategy aimed at slowing loss of kidney function and reducing cardiovascular risk. Until recently, however, the strongest outcome evidence for finerenone came from people with type 2 diabetes and CKD.
What FIND-CKD adds
The FIND-CKD trial changes that discussion. In this randomized trial, 1,584 adults with CKD without diabetes were assigned to finerenone or placebo. Participants had an eGFR of 25 to less than 90 mL/min/1.73 m², albuminuria, and were receiving renin–angiotensin system inhibition. Over 32 months, the annual eGFR decline was slower with finerenone: −3.3 versus −4.0 mL/min/1.73 m² per year, an adjusted difference of 0.7 mL/min/1.73 m² per year. A prespecified composite kidney or cardiovascular outcome was also lower with finerenone, although the event-based evidence was less definitive than the eGFR-slope result.
How to interpret the population
The practical message is not that every patient with CKD should receive finerenone. The trial population was selected: albuminuric CKD, background renin–angiotensin system blockade, and no diabetes. The results therefore support an expansion of the evidence base rather than an indiscriminate expansion of prescribing.
Hyperkalemia and monitoring
Hyperkalemia remains the key safety issue. In FIND-CKD, hyperkalemia events occurred in 17.0% of participants receiving finerenone and 13.3% receiving placebo; treatment discontinuation because of hyperkalemia occurred in 1.5% and 0.1%, respectively. This reinforces a familiar nephrology principle: effective renoprotective therapy often requires active potassium surveillance rather than therapeutic avoidance.
Where combination therapy may fit
The larger question is where finerenone fits into combination therapy. Modern CKD care is increasingly based on complementary mechanisms rather than a single dominant drug. The unanswered questions include the incremental benefit of finerenone when combined with contemporary SGLT2 inhibitor therapy, how benefits vary across different CKD etiologies, and which patients derive the greatest absolute benefit.
Bottom line
FIND-CKD provides evidence that finerenone can slow eGFR decline in selected patients with albuminuric CKD without diabetes. It is a meaningful expansion of the finerenone evidence base, but implementation should remain phenotype-driven, with particular attention to baseline and follow-up potassium.
Key clinical takeaways
- Finerenone now has randomized evidence in selected albuminuric CKD without diabetes.
- Hyperkalemia remains the principal monitoring issue.
- The findings support phenotype-based expansion of therapy, not universal prescribing.